JP2004527492A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527492A5
JP2004527492A5 JP2002567293A JP2002567293A JP2004527492A5 JP 2004527492 A5 JP2004527492 A5 JP 2004527492A5 JP 2002567293 A JP2002567293 A JP 2002567293A JP 2002567293 A JP2002567293 A JP 2002567293A JP 2004527492 A5 JP2004527492 A5 JP 2004527492A5
Authority
JP
Japan
Prior art keywords
formula
tremor
composition
group
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567293A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527492A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US10/081,501 external-priority patent/US6589985B2/en
Publication of JP2004527492A publication Critical patent/JP2004527492A/ja
Publication of JP2004527492A5 publication Critical patent/JP2004527492A5/ja
Pending legal-status Critical Current

Links

JP2002567293A 2001-02-27 2002-02-21 運動障害の予防もしくは治療における使用のためのカルバメート化合物 Pending JP2004527492A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168301P 2001-02-27 2001-02-27
US10/081,501 US6589985B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders
PCT/US2002/005542 WO2002067926A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating movement disorders

Publications (2)

Publication Number Publication Date
JP2004527492A JP2004527492A (ja) 2004-09-09
JP2004527492A5 true JP2004527492A5 (https=) 2005-12-22

Family

ID=26765643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567293A Pending JP2004527492A (ja) 2001-02-27 2002-02-21 運動障害の予防もしくは治療における使用のためのカルバメート化合物

Country Status (27)

Country Link
US (1) US6589985B2 (https=)
EP (1) EP1411917B1 (https=)
JP (1) JP2004527492A (https=)
KR (1) KR100858232B1 (https=)
CN (1) CN1262272C (https=)
AR (1) AR033426A1 (https=)
AT (1) ATE369130T1 (https=)
AU (1) AU2002247204B2 (https=)
BR (1) BR0207831A (https=)
CA (1) CA2439478C (https=)
CY (1) CY1106924T1 (https=)
CZ (1) CZ20032299A3 (https=)
DE (1) DE60221670T2 (https=)
DK (1) DK1411917T3 (https=)
ES (1) ES2291454T3 (https=)
HU (1) HUP0303344A3 (https=)
IL (2) IL157592A0 (https=)
MX (1) MXPA03007719A (https=)
MY (1) MY157373A (https=)
NO (1) NO20033803L (https=)
NZ (1) NZ551954A (https=)
PL (1) PL364679A1 (https=)
PT (1) PT1411917E (https=)
RS (1) RS50676B (https=)
RU (1) RU2294739C2 (https=)
TW (1) TWI331524B (https=)
WO (1) WO2002067926A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267629T1 (de) * 2000-07-21 2004-06-15 Ortho Mcneil Pharm Inc Verwendung von carbamat verbindungen zur vorbeugung oder behandlung von neuropathischen- , cluster- und migräneartigen kopfschmerzen
EP1383489B1 (en) * 2001-02-27 2007-05-09 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neurodegenerative disorders
ATE435014T1 (de) 2001-07-16 2009-07-15 Ortho Mcneil Pharm Inc Carbamate verbindungen zur vorbeugung oder behandlung von neuropathischen schmerzen
EP1890684B1 (en) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato
ES2385087T3 (es) * 2005-07-26 2012-07-18 Sk Biopharmaceuticals Co., Ltd Procedimientos para tratar trastornos relacionados con sustancias
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
BR112012010670A2 (pt) 2009-11-06 2016-04-12 Sk Biopharmaceuticals Co Ltd métodos para tratamento de distúrbio de défict de atenção/hiperatividade
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN105189451A (zh) 2013-03-12 2015-12-23 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
US11033531B2 (en) * 2016-12-14 2021-06-15 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR20230044274A (ko) * 2020-08-31 2023-04-03 (주)바이오팜솔루션즈 신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Similar Documents

Publication Publication Date Title
JP2004527492A5 (https=)
JP2004517087A5 (https=)
JP2004500426A5 (https=)
RU2003128985A (ru) Производные карбамата для применения для предупреждения или лечения расстройств движений
JP2005511698A5 (https=)
JP2004534816A5 (https=)
CA2660529A1 (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL189003A0 (en) Methods for treating substance-related disorders
JP2004525905A5 (https=)
JPWO2023195529A5 (https=)
JP2004533415A5 (https=)
RU2003128984A (ru) Производные карбаматов для использования для лечения боли
WO2007008562A3 (en) Carbamate compounds for use in treating neurodegenerative disorders
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
JP2004523556A5 (https=)
CA2439475A1 (en) Carbamate compounds for use in preventing or treating bipolar disorder
JP2005538974A5 (https=)
RU2003128983A (ru) Производные карбаматов для предотвращения или лечения психотических нарушений
MA27605A1 (fr) Dérivés de morpholine destinés à être utilisés comme agonistes de la dopamine dans le traitement d'un dysfonctionnement sexuel
JP2007518798A5 (https=)
EA202191075A1 (ru) Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний
JP2005517634A5 (https=)
WO2002007822A3 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
JP2007521272A5 (https=)
JP2005516952A5 (https=)